BABYF - Else Nutrition Is Accelerating Growth After Successfully Establishing Its Initial Sales Platform
- Despite Covid-related delays, Else is successfully scaling operations.
- Management expects to top $10 million in annual revenue in just its second year of commercial operations.
- There are several imminent developments that are potential catalysts for share price appreciation.
- Else is conducting clinical trials to validate product benefits for targeted markets and for regulatory approval for infant formula, which is likely to become Else's lead product sometime next year.
For further details see:
Else Nutrition Is Accelerating Growth After Successfully Establishing Its Initial Sales Platform